JPH07508530A - 内臓の痛みおよび偏頭痛の治療薬 - Google Patents

内臓の痛みおよび偏頭痛の治療薬

Info

Publication number: JPH07508530A
Authority: JP; Japan
Prior art keywords: dose; activity; receptor antagonist; composition according; treatment
Prior art date: 1992-07-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP6503078A

Other languages

English (en)

Japanese (ja)

Inventor

サンガー，ガレス・ジョン

バナー，スティーブン・エドワード

Original Assignee

スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-03

Filing date

1993-06-30

Publication date

1995-09-21

1993-06-30 Application filed by スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー filed Critical スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー

1995-09-21 Publication of JPH07508530A publication Critical patent/JPH07508530A/ja

Status Pending legal-status Critical Current

Links

208000009935 visceral pain Diseases 0.000 title claims description 6
229940079593 drug Drugs 0.000 title claims description 5
239000003814 drug Substances 0.000 title claims description 5
208000019695 Migraine disease Diseases 0.000 title claims description 4
230000000694 effects Effects 0.000 claims description 15
229940044551 receptor antagonist Drugs 0.000 claims description 11
239000002464 receptor antagonist Substances 0.000 claims description 11
102000035037 5-HT3 receptors Human genes 0.000 claims description 10
108091005477 5-HT3 receptors Proteins 0.000 claims description 10
238000000034 method Methods 0.000 claims description 9
229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 claims description 7
MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 7
229960003727 granisetron Drugs 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 7
238000011282 treatment Methods 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 6
238000010171 animal model Methods 0.000 claims description 5
208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
229960004503 metoclopramide Drugs 0.000 claims description 4
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 4
238000012360 testing method Methods 0.000 claims description 4
208000002193 Pain Diseases 0.000 claims description 3
SPKBYQZELVEOLL-QDMKHBRRSA-N chembl2111147 Chemical group N([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC2=C1OC(C)(C)C2 SPKBYQZELVEOLL-QDMKHBRRSA-N 0.000 claims description 3
230000036407 pain Effects 0.000 claims description 3
208000024891 symptom Diseases 0.000 claims description 3
229950001074 zatosetron Drugs 0.000 claims description 3
229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 2
238000011321 prophylaxis Methods 0.000 claims 2
206010069055 Vulvovaginal pain Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
206010027599 migraine Diseases 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
230000009278 visceral effect Effects 0.000 description 6
229940035676 analgesics Drugs 0.000 description 4
239000000730 antalgic agent Substances 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 description 1
ILXWRFDRNAKTDD-GOOCMWNKSA-N 3,3-dimethyl-n-[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2h-indole-1-carboxamide Chemical compound C1C(C)(C)C2=CC=CC=C2N1C(=O)NC(C1)C[C@H]2CC[C@@H]1N2C ILXWRFDRNAKTDD-GOOCMWNKSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
210000002011 intestinal secretion Anatomy 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
229960005343 ondansetron Drugs 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000031893 sensory processing Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
229960003688 tropisetron Drugs 0.000 description 1
UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP6503078A 1992-07-03 1993-06-30 内臓の痛みおよび偏頭痛の治療薬 Pending JPH07508530A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9214184.5		1992-07-03
GB929214184A GB9214184D0 (en)	1992-07-03	1992-07-03	Pharmaceuticals
PCT/GB1993/001377 WO1994001095A2 (fr)	1992-07-03	1993-06-30	Medicaments pour le traitement de douleurs viscerales et de migraines

Publications (1)

Publication Number	Publication Date
JPH07508530A true JPH07508530A (ja)	1995-09-21

Family

ID=10718169

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP6503078A Pending JPH07508530A (ja)	1992-07-03	1993-06-30	内臓の痛みおよび偏頭痛の治療薬

Country Status (7)

Country	Link
EP (1)	EP0650355A1 (fr)
JP (1)	JPH07508530A (fr)
KR (1)	KR950702112A (fr)
AU (1)	AU4507693A (fr)
CA (1)	CA2139440A1 (fr)
GB (1)	GB9214184D0 (fr)
WO (1)	WO1994001095A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002503689A (ja) *	1998-02-21	2002-02-05	アスタメディカアクチエンゲゼルシャフト	トラマドールを含有する製薬的組み合わせ剤

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5998409A (en) *	1992-03-12	1999-12-07	Smithkline Beecham Plc	Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) *	1992-03-12	1998-12-22	Smithkline Beecham P.L.C.	Condensed indole derivatives as 5HT4 -receptor antagonists
US5726187A (en) *	1992-10-16	1998-03-10	Smithkline Beecham Plc	N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists
GB9721139D0 (en)	1997-10-07	1997-12-03	Glaxo Group Ltd	Medicaments
ATE434437T1 (de) *	1999-02-18	2009-07-15	Novasearch Ag	Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
TWI263496B (en) *	1999-12-10	2006-10-11	Novartis Ag	Pharmaceutical combinations and their use in treating gastrointestinal disorders
GB0216027D0 (en)	2002-07-10	2002-08-21	Arachnova Therapeutics Ltd	New therapeutic use
JP2006516977A (ja)	2003-01-13	2006-07-13	ダイノゲンファーマシューティカルズ，インコーポレイテッド	悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
GB0302662D0 (en) *	2003-02-05	2003-03-12	Strakan Ltd	Transdermal granisetron
US20060263421A1 (en)	2005-05-18	2006-11-23	Abeille Pharmaceuticals Inc	Transdermal Method and Patch for Nausea

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE86110T1 (de) *	1984-12-20	1993-03-15	Sandoz Ag	Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.
GB8617994D0 (en) *	1986-07-23	1986-08-28	Glaxo Group Ltd	Heterocyclic compounds
EP0254584B1 (fr) *	1986-07-25	1992-10-07	Beecham Group Plc	Composés azabicycliques, procédé pour leur préparation et leur utilisation pharmaceutique
GB8623819D0 (en) *	1986-10-03	1986-11-05	Glaxo Group Ltd	Heterocyclic compounds
GB8812002D0 (en) *	1988-05-20	1988-06-22	Glaxo Group Ltd	Chemical compounds
GB8630080D0 (en) *	1986-12-17	1987-01-28	Glaxo Group Ltd	Medicaments
GB8806990D0 (en) *	1988-03-23	1988-04-27	Beecham Group Plc	Novel compounds
GB8701022D0 (en) *	1987-01-19	1987-02-18	Beecham Group Plc	Treatment
DE3852145T2 (de) *	1987-02-18	1995-04-06	Beecham Group Plc	Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
EP0289170B1 (fr) *	1987-04-25	1993-06-23	Beecham Group Plc	Composés azabicycliques, leur procédé de préparation et compositions pharmaceutiques les contenant
GB8723157D0 (en) *	1987-10-02	1987-11-04	Beecham Group Plc	Compounds
JPH01258673A (ja) *	1987-10-22	1989-10-16	Glaxo Group Ltd	ケトン誘導体
ATE108791T1 (de) *	1987-11-04	1994-08-15	Beecham Group Plc	Neue 4-oxobenzotriazine und 4-oxochinazoline.
EP0336759A1 (fr) *	1988-04-07	1989-10-11	Glaxo Group Limited	Dérivés d'imidazole
GB8814277D0 (en) *	1988-06-16	1988-07-20	Glaxo Group Ltd	Chemical compounds
IT1226389B (it) *	1988-07-12	1991-01-15	Angeli Inst Spa	Nuovi derivati ammidinici e guanidinici
US5017573A (en) *	1988-07-29	1991-05-21	Dainippon Pharmaceutical Co., Ltd.	Indazole-3-carboxylic acid derivatives
EP0356098A3 (fr) *	1988-08-15	1990-07-25	Glaxo Group Limited	Dérivés de lactames
GB8820650D0 (en) *	1988-09-01	1988-10-05	Glaxo Group Ltd	Medicaments
US5173493A (en) *	1988-09-27	1992-12-22	Fujisawa Pharmaceutical Company, Ltd.	Pyridoindole derivatives and processes for preparation thereof
AU627221B2 (en) *	1988-09-27	1992-08-20	Fujisawa Pharmaceutical Co., Ltd.	Pyridoindole derivatives and processes for preparation thereof
GB8823980D0 (en) *	1988-10-13	1988-11-23	Glaxo Group Ltd	Chemical compounds
GB8829079D0 (en) *	1988-12-13	1989-01-25	Beecham Group Plc	Novel compounds
CA2004911A1 (fr) *	1988-12-22	1990-06-22	Mitsuaki Ohta	Derives de 4,5,6,7-tetrahydrobenzimidazole
AU626980B2 (en) *	1989-02-02	1992-08-13	Astellas Pharma Inc.	Tetrahydrobenzimidazole derivatives
GB8904551D0 (en) *	1989-02-28	1989-04-12	Glaxo Group Ltd	Chemical compounds
EP0387431A1 (fr) *	1989-03-14	1990-09-19	Beecham Group Plc	Dérivés d'imidazole, procédés de leur préparation et leur application comme produits pharmaceutiques
GB8916682D0 (en) *	1989-07-21	1989-09-06	Beecham Group Plc	Pharmaceutical compounds
DK443489D0 (da) *	1989-09-08	1989-09-08	Ferrosan As	Substituerede urinstofforbindelser, deres fremstilling og anvendelse
US4992461A (en) *	1989-09-11	1991-02-12	G. D. Searle & Co.	N-azabicyclo(3.3.0)octane amides of aromatic acids, compositions, and methods of use thereof
US5126343A (en) *	1989-09-11	1992-06-30	G. D. Searle & Co.	N-azabicyclo [3.3.0]octane amides of aromatic acids
WO1991007402A1 (fr) *	1989-11-17	1991-05-30	Pfizer Inc.	Amides et esters azabicyliques antagonistes du recepteur de 5-ht¿3?
DK40890D0 (da) *	1990-02-16	1990-02-16	Ferrosan As	Substituerede urinstofforbindelser, deres fremstilling og anvendelse
EP0450757A3 (en) *	1990-02-22	1993-09-15	Glaxo Group Limited	Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
US5140023A (en) *	1990-04-27	1992-08-18	G. D. Searle & Co.	Azatetracycle compounds
GB9020927D0 (en) *	1990-09-26	1990-11-07	Beecham Group Plc	Pharmaceuticals
GB9027487D0 (en) *	1990-12-19	1991-02-06	Beecham Group Plc	Pharmaceuticals
AU1161292A (en) *	1991-01-09	1992-08-17	Smithkline Beecham Plc	Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB9103839D0 (en) *	1991-02-23	1991-04-10	Smithkline Beecham Plc	Pharmaceuticals
US5260303A (en) *	1991-03-07	1993-11-09	G. D. Searle & Co.	Imidazopyridines as serotonergic 5-HT3 antagonists
US5137893A (en) *	1991-03-07	1992-08-11	G. D. Searle & Co.	Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
EP0517984A1 (fr) *	1991-06-11	1992-12-16	Merrell Dow Pharmaceuticals Inc.	Derivés d'analogues d'amide de quinolizines à pont méthano
DE69319939T2 (de) *	1992-02-04	1999-02-18	Eisai Co., Ltd., Tokio/Tokyo	Aminobenzoesäure Derivate

1992
- 1992-07-03 GB GB929214184A patent/GB9214184D0/en active Pending
1993
- 1993-06-30 WO PCT/GB1993/001377 patent/WO1994001095A2/fr not_active Ceased
- 1993-06-30 CA CA002139440A patent/CA2139440A1/fr not_active Abandoned
- 1993-06-30 AU AU45076/93A patent/AU4507693A/en not_active Abandoned
- 1993-06-30 JP JP6503078A patent/JPH07508530A/ja active Pending
- 1993-06-30 EP EP93914854A patent/EP0650355A1/fr not_active Withdrawn
1994
- 1994-12-31 KR KR1019940704887A patent/KR950702112A/ko not_active Withdrawn

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002503689A (ja) *	1998-02-21	2002-02-05	アスタメディカアクチエンゲゼルシャフト	トラマドールを含有する製薬的組み合わせ剤

Also Published As

Publication number	Publication date
GB9214184D0 (en)	1992-08-12
EP0650355A1 (fr)	1995-05-03
WO1994001095A2 (fr)	1994-01-20
KR950702112A (ko)	1995-06-19
AU4507693A (en)	1994-01-31
WO1994001095A3 (fr)	1994-04-14
CA2139440A1 (fr)	1994-01-20

Publication	Publication Date	Title
Wen et al.	1982	Suppression of withdrawal symptoms by dynorphin in heroin addicts
JPH07508530A (ja)	1995-09-21	内臓の痛みおよび偏頭痛の治療薬
JP2002537332A (ja)	2002-11-05	内臓痛を予防及び治療するためのガバペンチン誘導体
US20230218531A1 (en)	2023-07-13	Long acting opioid antagonists
CN101622013A (zh)	2010-01-06	包含丁丙诺啡和纳洛酮的改善的药用组合物
US5432176A (en)	1995-07-11	Method of retarding the progression of chronic renal failure
KR20010021865A (ko)	2001-03-15	카파 작용제 항소양성 약학적 조성물 및 이를 이용한소양증의 치료 방법
JP2002527392A (ja)	2002-08-27	末梢的に作用する抗掻痒アヘン剤
JPH10505823A (ja)	1998-06-09	脱髄性及び髄鞘形成障害性疾患を抑制する方法
JPH11514654A (ja)	1999-12-14	外傷による脳損傷の治療方法
CN112516284B (zh)	2021-12-21	一种短肽在制备具有消除吗啡耐受性作用的产品中的应用
Hosseini et al.	2019	Neuroprotective effects of lipopolysaccharide and naltrexone co‑preconditioning in the photothrombotic model of unilateral selective hippocampal ischemia in rat
JPH07506333A (ja)	1995-07-13	勃起機能不全症治療用ピリジルグアニジン化合物
JPH09500620A (ja)	1997-01-21	極小の運動遮断で鎮痛効果を示す医薬の製造におけるロピバカインの使用
Neal et al.	1986	Ketanserin and pirenperone attenuate acute morphine withdrawal in rats
Oosterlinck et al.	1980	Preliminary clinical experience with dezocine, a new potent analgesic
Gerring	1989	Effects of pharmacological agents on gastrointestinal motility
Doherty et al.	1994	Stimulatory effects of quinelorane on yawning and penile erection in the rat
Shaw et al.	1956	Benzyldimethylbufotenin, a powerful antimetabolite of serotonin
WO2006106358A2 (fr)	2006-10-12	Utilisation d'antagonistes des recepteurs nk-3 dans le traitement de la nausee et des vomissements
Mourad et al.	1995	Role of 5-hydroxytryptamine in intestinal water and electrolyte movement during gut anaphylaxis.
PELNER	1947	Anaphylaxis to the injection of nicotinic acid (niacin); successful treatment with epinephrine
JP2003524573A (ja)	2003-08-19	神経精神性疾患用ニコチンアンタゴニスト
Warren et al.	1985	A double-blind comparison of dezocine and morphine in patients with acute renal and ureteral colic
US20250127765A1 (en)	2025-04-24	Rapid induction with monthly injectable buprenorphine extended-release

JPH07508530A - 内臓の痛みおよび偏頭痛の治療薬 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=10718169

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (10)

Family Cites Families (43)

Cited By (1)

Also Published As

Similar Documents